Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SNT-5505,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Syntara Announces Positive Interim Data in Phase 2 Study of SNT-5505 in Myelofibrosis
Details : SNT-5505 is a lysyl oxidase inhibitor small molecule drug candidate, which is currently being evaluated in combination with ruxolitinib for the treatment of myelofibrosis.
Product Name : SNT-5505
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2024
Lead Product(s) : SNT-5505,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable